BioXcel Therapeutics files Form 144 for 6,560 shares

BioXcel Therapeutics, Inc. submitted a Form 144 notice relating to a proposed sale of 6,560 shares of Common Stock.

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. submitted a Form 144 notice relating to a proposed sale of 6,560 shares of Common Stock. The shares are tied to the vesting of restricted stock unit awards dated 05/04/2026 and were granted as part of issuer equity compensation plan.

Insights

Securities Counsel

Form 144 notifies the market of a proposed sale of vested RSU shares.

Form 144 is a notice of intent to sell restricted or control securities under resale rules. The filing lists 6,560 shares tied to RSU vesting on 05/04/2026, described as granted under the issuer's equity compensation plan.

Timing, broker/dealer methods, and whether sales will occur immediately are not stated in the excerpt; subsequent filings may indicate executed dispositions or broker details.

Key Figures

Form type: Form 144 Shares to be sold: 6,560 shares Reference number: 30,877,605

3 metrics

Form type Form 144 Notice of proposed sale

Shares to be sold 6,560 shares Vesting of restricted stock unit awards on <date>05/04/2026</date>

Reference number 30,877,605 Listed in the securities information block with <date>05/20/2026</date>

Key Terms

restricted stock unit, Form 144, vesting

3 terms

restricted stock unit financial

"Vesting of restricted stock unit awards | BioXcel Therapeutics, Inc."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

vesting financial

"Securities To Be Sold | 05/04/2026 | Vesting of restricted stock unit awards"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BioXcel Therapeutics' Form 144 for BTAI mean?

It notifies the SEC of an affiliate's intention to sell 6,560 shares of Common Stock tied to RSU vesting on 05/04/2026. The filing is a procedural disclosure, not proof that the shares have been sold.

Are the 6,560 shares from compensation or market purchases for BTAI?

The excerpt states the shares arise from the vesting of restricted stock unit awards granted as part of the issuer's equity compensation plan on 05/04/2026. They are compensation-related, not open-market purchases.

Does the Form 144 say who will receive sale proceeds for BTAI shares?

The provided excerpt does not specify proceeds recipients. The filing describes securities to be sold due to RSU vesting; it does not state the cash‑flow treatment or who will receive proceeds.

Is the number 30,877,605 shown in the excerpt relevant to outstanding shares?

The excerpt includes the number 30,877,605 alongside a 05/20/2026 and NASDAQ, which appears in the securities information block. The filing text does not explicitly label this number within the provided excerpt.

Will Form 144 trigger immediate sales of BTAI shares?

Form 144 is a notice of intent and does not itself execute a sale. The excerpt lists the proposed sale amount (6,560 shares) tied to RSU vesting; it does not state whether or when brokered sales will occur.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001847919
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BioXcel Therapeutics, Inc.
SEC File Number	001-38410
Address of Issuer	555 LONG WHARF DRIVE NEW HAVEN CONNECTICUT 06511
Phone	203-643-8060
Name of Person for Whose Account the Securities are To Be Sold	Rodriguez Javier
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	6560	7108.80	30877605	05/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/04/2026	Vesting of restricted stock unit awards	BioXcel Therapeutics, Inc.			6560	05/04/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	05/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Javier Rodriguez
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)